TVT has become the epicenter of innovation and collaboration in the structural heart arena over its 16-year history. The meeting brings together world-renowned experts and master operators to help translate novel discoveries into practical therapies for patients with valvular heart disease.
TVT’s late-breaking clinical science will highlight the latest advances in transcatheter aortic valve replacement as well as mitral, tricuspid, and left atrial appendage occlusion therapies. Data from these trials will help guide the selection of patients who will benefit most from these procedures and help define optimal treatment strategies, tools, and techniques for new and emerging treatments.
Thursday, June 8, 2023
Late-Breaking Clinical Science I
Mitral Valve Disease
Innovation & Clinical Science, Room 106
11:00 AM – 12:15 PM MST
- Contemporary, Core-Lab Assessed, Acute Clinical Outcomes from 2000+ Patients with Mitral Regurgitation Treated with the 3rd and 4th Generation MitraClip™ Systems: Results from the EXPANDed Post Approval Studies
- Longer-Term Clinical and Echocardiography Follow-up of Transcatheter Mitral Valve Replacement with the Trans-apical Intrepid System
- Contemporary Outcomes of Transcatheter Transeptal Mitral Valve in Valve in the United States
- Mitral Valve Repair versus Replacement after Transcatheter Edge-to-Edge Mitral Repair: Results from The CUTTING-EDGE Registry
- Pressure Gradients and Mortality Following Transcatheter Mitral Valve in Valve and Valve in Ring
Friday, June 9, 2023
Late-Breaking Clinical Science II
Aortic Valve Disease (TAVR)
Innovation & Clinical Science, Room 106
11:00 AM – 12:15 PM MST
- 5 Year Outcomes of TAVI Patients with Prosthesis-Patient Mismatch
- Transcatheter Aortic Valve Replacement Using a Balloon-Expandable Valve in Patients with Type-0 Bicuspid Aortic Valve Stenosis
- Real-World Early Outcomes of Evolut FX Versus PRO+ Transcatheter Aortic Valve Replacement
- Analysis of New Permanent Pacemaker Implantation in the PORTICO NG Study Utilizing the Intra-Annular, Self-Expandable Navitor™ Transcatheter Aortic Heart Valve
- Three-Year Outcomes from the Evolut Low Risk TAVR Bicuspid Study
Saturday, June 10, 2023
Late-Breaking Clinical Science III
Early Human Experiences – Mitral Valve Replacement Innovation
Innovation & Clinical Science, Room 106
- Innovalve First-in-Human TMVR Experience (TWIST FIH): Clinical Outcomes and Echocardiography Evidence for Reverse Remodeling
- Early Human Experience with the Cephea Transseptal TMVR System in Complex Mitral Anatomies
- Bioprosthetic Surgical Valves in Intermediate-risk Patients: 1-Year Outcomes of the PARTNER 3 Mitral Valve-in-Valve Study
- AltaValve Early Feasibility Study: Preservation of Mitral Valve Physiology Using a Passive Fixation TMVR Device
- Trans-septal Mitral Valve Replacement with HighLife Valve in a Patient with Moderate-Severe Mitral Regurgitation
In addition to the 15 late-breaking science studies, TVT will feature:
- More than 30 live cases from 13 leading academic medical centers in North America and Europe
- Six tracks: Imaging, Left Atrial Appendage (LAA)/Patent Foramen Ovale (PFO), Heart Failure, Mitral, Tricuspid, and TAVR
- Case-based sessions and hands-on training
- Moderated poster presentations
- And much more!
Additional information on TVT is available at https://tvt2023.crfconnect.com/.
HOW TO REGISTER:
Media may apply for press registration by emailing [email protected].
About CRF
The Cardiovascular Research Foundation (CRF) is one of the world’s leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 30 years, CRF has helped accelerate medical breakthroughs and educated doctors on the latest treatments for heart disease. CRF’s centers of excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team. For more information, visit www.crf.org.
###